Exelixis Inc (EXEL)vsBeiGene, Ltd. (ONC)
EXEL
Exelixis Inc
$42.79
+2.92%
HEALTHCARE · Cap: $11.15B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 130% more annual revenue ($5.34B vs $2.32B). EXEL leads profitability with a 33.7% profit margin vs 5.4%. EXEL trades at a lower P/E of 14.9x. EXEL earns a higher WallStSmart Score of 72/100 (B).
EXEL
Strong Buy72
out of 100
Grade: B
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.0%
Fair Value
$130.10
Current Price
$42.78
$87.31 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 36 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 39.4%
Earnings expanding 84.2% YoY
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 33.7% and operating margin at 39.4%.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
EXEL profiles as a mature stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
EXEL generates stronger free cash flow (332M), providing more financial flexibility.
Bottom Line
EXEL scores higher overall (72/100 vs 42/100), backed by strong 33.7% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?